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Abstract: Since 2010, six drugs have been approved for the treatment of castration-resistant 
prostate cancer, i.e., CYP17 inhibitor Abiraterone, androgen receptor antagonist Enzalutamide, 
cytotoxic agent Cabazitaxel, vaccine Sipuleucel-T, antibody Denosumab against receptor 
activator of nuclear factor kappa B ligand and radiopharmaceutical Alpharadin. All these 
drugs demonstrate improvement on overall survival, expect for Denosumab, which 
increases the bone mineral density of patients under androgen deprivation therapy and 
prolongs bone-metastasis-free survival. Besides further CYP17 inhibitors (Orteronel, 
Galeterone, VT-464 and CFG920), androgen receptor antagonists (ARN-509, ODM-201, 
AZD-3514 and EZN-4176) and vaccine Prostvac, more drug candidates with various 
mechanisms or new indications of launched drugs are currently under evaluation in 
different stages of clinical trials, including various kinase inhibitors and platinum 
complexes. Some novel strategies have also been proposed aimed at further potentiation of 
antitumor effects or reduction of side effects and complications related to treatments. 
Under these flourishing circumstances, more investigations should be performed on the 
optimal combination or the sequence of treatments needed to delay or reverse possible 
resistance and thus maximize the clinical benefits for the patients. 
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The aging of population increases the incidence of prostate cancer (PCa) because the median age of 
PCa patients being diagnosed is 67. Estimation has been made that in the US nearly a quarter-million 
PCa cases emerged in 2012 accounting for 29% of the total new cancer cases [1]. In contrast, 28,170 
patients died of PCa composing only 9% of the total cancer related death [1]. This difference is 
probably because most of the PCa patients were identified in the early stages and therefore could be 
cured with local therapies, such as prostatectomy, radiation and cryotherapy, with the five-year 
survival approaching 100% [2]. However, for advanced metastatic cases these treatments show  
little benefit and without effective control the patients ineluctably die. Androgen deprivation and 
chemotherapy are currently standard treatments for these patients. However, after long term application 
nearly all patients are no longer sensitive to these treatments. Progression or relapse happen even under 
the circumstance that the plasma concentrations of testosterone are suppressed to around 50 ng/dL by 
castration or gonadotropin-releasing hormone (GnRH) analogues, while the effects of the remaining 
androgens are blocked by androgen receptor (AR) antagonists. This situation is termed as  
castration-resistant prostate cancer (CRPC), which has been mis-comprehended as “androgen 
independent”. However, recent research revealed that CRPC is still driven by hormones [3]. Many 
possible mechanisms have been proposed for CRPC, such as super-sensitivity of tumor cells to low 
levels of androgen, intratumoral androgen para-/autocrine production, AR mutation and ligand 
independent AR activation. Since 2010, six drugs have been approved for the treatment of CRPC. 
These drugs either show improvement on overall survival or relieve the symptoms regarding bones, 
which are the most frequent sites that metastases happen due to the abundant growth factors facilitating 
the proliferation of cancer cells [4]. More drug candidates are currently under evaluation in different 
stages of clinical trials and some novel strategies have also been proposed aimed at further potentiation 
of antitumor effects or reduction of side effects and complications related to treatments. 
2. CYP17 Inhibitor Abiraterone 
Hormone therapy is based on the observation that up to 80% of PCa proliferation is stimulated by 
androgens [5]. Therefore, orchiectomy or GnRH analogues (chemical castration) have been employed 
to reduce androgen levels because around 90% of androgens are produced in testes. However, it is 
apparent that they cannot prevent the biosyntheses of androgen inside adrenals and tumor cells. This 
leak results in sufficient androgens inside the prostate to continue stimulating PCa cells [6]. In contrast, 
the inhibition of 17α-hydroxylase-17,20-lyase (CYP17) is a superior approach to eradicate androgen 
secretion because this enzyme is pivotal in androgen biosynthesis regardless of production location. 
Abiraterone (Scheme 1) is the first CYP17 inhibitor, launched in 2011 as the acetate prodrug.  
It competitively inhibits the enzyme via the coordination of its sp2 hybrid pyridyl N to heme iron, 
which is the reactive centre of CYP enzymes for activating O2 and oxidizing the substrates. Due to the 
common catalytic mechanism across the CYP family, this inhibitory artifice has been successfully 
exploited in not only CYP17 inhibitors [7–14], but also inhibitors of other steroidogenic CYP 
enzymes, e.g., aromatase (CYP19) [15–19], 11β-hydroxylase (CYP11B1) [20–22] and aldosterone 
synthase (CYP11B2) [23–29]. Abiraterone significantly inhibits both activities of CYP17,  
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i.e., 17α-hydroxylase and C17-20 lyase, with similar potency (IC50 of 4 and 2.9 nM, respectively) in a 
human testicular microsome assay [30]. This potent inhibition leads to a reduction of the  
plasma testosterone concentrations to less than 1 ng/dL [3]. However, the plasma levels of  
11-deoxycorticosterone (DOC) and corticosterone are boosted by 10- and 40-fold, respectively [18], 
which result from the inhibition of 17α-hydroxylase activity and CYP11B1 [31] via a 2-fold decrease 
of cortisol concentration and the subsequent 5-fold promotion of ACTH secretion [3]. The elevation of 
mineralocorticoids leads to hypokalemia, hypertension and edema, which have to be suppressed by the 
co-application of Prednisone. On the other hand, Abiraterone not only eliminates around 80% of the 
steady-state AR in LNCaP cells, but also blocks the AR mediated transactivation [32]. This 
antagonism of AR may also contribute to the anti-tumor effects. When Abiraterone is orally applied as 
an acetate prodrug (1000 mg per day), the release of free Abiraterone is very rapid and thorough so 
that Abiraterone reaches maximum plasma concentration (226 ± 178 ng/mL) in 2 h [33], whereas 
Abiraterone acetate is undetectable in plasma [33,34]. In contrast, approximately half of the applied 
Abiraterone is excreted as unchanged Abiraterone acetate via feces [33,35], which might indicate a 
poor gastrointestinal absorption. Around 70% of patients, who are naïve to Ketoconazole and 
Docetaxel, show at least 50% decline of prostate specific antigen (PSA) levels [36–38], which is a 
major biomarker in the treatment of CRPC; While for the patients with previous treatments of these 
two drugs, the response ratio is significantly lower [36–39]. The same trend is also observed for the 
delay of PSA regression [33–39]. Furthermore, in half of the CRPC patients, the counts of circulating 
tumor cells are decreased to less than 5 per 7.5 mL blood after Abiraterone treatment [37,38,40]. 
Symptoms like pain [41,42], pathological fracture [42], spinal cord compression [42] and fatigue [43] 
are significantly improved as well. More important is the improvement of survival. In post-Docetaxel 
metastatic CRPC patients, Abiraterone prolongs the median overall survival (15.8 months) by 4.6 months 
compared to placebo [44,45]. Accordingly, the median radiologic progression-free survival is also 
improved to 5.6 months, which is around 2 months longer than that of the placebo arm [44,45]. 
Echoing the better PSA response of Docetaxel-naïve cohort, Abiraterone exhibits a longer median 
radiologic progression-free survival of 16.5 months in chemotherapy-naïve CRPC patients, which 
doubles that of the control group (8.3 months) [41]. The initiation of chemotherapy is also delayed by 
8.4 months [41]. Due to these apparent benefits, the clinical trial was un-blinded after the interim 
analysis and all patients were crossed to the Abiraterone group. Although the median overall survival 
in the Abiraterone arm was therefore not reached in a median follow-up period of 22.2 months, it is 
clearly longer that of the placebo group (27.2 months) [41]. 
Scheme 1. Structures of Abiraterone, Enzalutamide and Cabazitaxel. 
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3. AR Antagonist Enzalutamide 
The stimulation of androgens on PCa cancer cells is mediated by AR, which is an intracellular 
transcription factor floating in cytoplasm. The binding of androgen disassociates AR from heat shock 
proteins and triggers homodimerization, phosphorylation and subsequent translocation into the 
nucleus. After binding to the androgen response element on DNA, transcription cofactors are recruited 
to initiate the transcription of the corresponding genes leading to mitogenic effects. Besides, activated 
AR also interacts directly with various kinase signaling pathways [46,47] promoting the survival and 
proliferation of PCa cells. AR antagonism is therefore an elegant way of PCa treatment and is 
employed in combination with GnRH analogues to compose combined androgen blockade. However, 
after the progression to CRPC, in which AR is highly over-expressed [48], the first generation AR 
antagonists, such as Flutamide and Bicalutamide, are impotent largely because of the relatively lower 
affinity compared to dihydrotestosterone (DHT)—the natural substrate of AR and the most potent 
androgen. These drugs also exhibit partial agonism activity [48] demonstrated by the withdrawal effect 
observed in the antiandrogen therapy [49]. Moreover, around 15%–30% of patients, who have received 
long term antiandrogen therapy, develop AR mutations [50], in particular W741C, which recognizes 
Bicalutamide as an agonist [51]. Fortunately, the second generation AR antagonist Enzalutamide that 
was launched in 2012 avoids these problems. Enzalutamide exhibits an 8-fold higher AR affinity than 
Bicalutamide and shows no agonism in the presence of W741C mutation and highly over-expressed 
AR [52]. Forkhead box transcription factor A, which presets chromatin and thus facilitates the binding 
of activated AR, only slightly attenuates the antagonism of Enzalutamide to AR, whereas it totally 
corrupts that of Bicalutamide [53]. Besides the antagonism of AR, including competing with 
androgens, inhibiting AR translocation into nucleus and impairing its DNA binding and co-activator 
recruiting, Enzalutamide also induces apoptosis of VCaP cells that exhibit amplified AR gene [52]. In 
a LNCaP/AR xenograft model in castrated male mice, Enzalutamide led to significant tumor 
regression [52]. The antitumor effects were further evidenced in clinical trials. More than half of 
patients under Enzalutamide treatment show serum PSA declines of over 50% [54,55]. The counts of 
circulating tumor cells as another important biomarker are also turned favorably in around 50% of 
patients [54]. Enzalutamide exhibits a 6-fold higher soft-tissue response rate compared to the placebo, 
improves life quality and delays PSA progression and emergence of the first skeletal-related event [55]. 
These benefits are caused by the on-target effects, i.e., the antagonism of AR, as demonstrated directly 
by positron emission tomography (PET) imaging with 18F-fluoro-5α-dihydrotestosterone [54]. Although 
seizure is observed in some patients, Enzalutamide is generally tolerable with the most common 
adverse effect of dose-dependent fatigue [55]. More importantly, the risk of death is reduced by 37% 
in the CRPC patients having previously received chemotherapy with the median overall survival of 
18.4 months [55]. The median radiographic progression-free survival is improved accordingly to  
8.3 months as well [55]. Currently, another phase III clinical trial is ongoing on Docetaxel-naïve 
CRPC patients and the results are eagerly expected. 
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4. Cytotoxic Cabazitaxel 
Until 2010, Docetaxel was the last defense line for CRPC and the only drug demonstrating survival 
benefits [56]. Patients showing no response or progression after Docetaxel therapy can only be 
managed with Prednisone and Mitoxantrone for palliative purpose. Cabazitaxel, in contrast, is the first 
agent to improve overall survival in post-Docetaxel patients [57]. As a member of the taxane class, 
Cabazitaxel unfolds the cytotoxic activity via the same mechanism as Docetaxel by binding to the 
tubulin to inhibit microtubule depolymerization and thus arresting mitosis. However, Cabazitaxel 
shows much less affinity to the ATP-dependent drug efflux pump P-glycoprotein (P-gp1) compared to 
Docetaxel [58]. Since P-gp1 is responsible for multi-drug resistance, this low affinity probably 
contributes to the superiority of Cabazitaxel over Docetaxel. Cabazitaxel exhibits a terminal half-life 
of 77 h after intravenous application. It is metabolized in liver by CYP3A4, CYP3A5 and CYP2C8 [58]. 
Co-application of the inducers or inhibitors of these enzymes should therefore be avoided. Grade 4 
neutropenia as the dose limiting toxicity has been observed at 25 mg/m2 every 3 weeks [58], hence this 
dose was applied in the following phase III clinical trials. In post-Docetaxel CRPC patients, the 
clinical efficacy of Cabazitaxel plus Prednisone was compared to that of the combination of 
Mitoxantrone and Prednisone. An improved overall survival of 15.1 months was demonstrated in 
patients under Cabazitaxel treatment in contrast to 12.7 months in the Mitoxantrane arm within a 
median follow-up of 12.8 months [58]. Moreover, the median progression-free survival (2.8 months), 
the PSA response ratio (39%) and the time to PSA progression (6.4 months) are twice as high as those 
of the Mitoxantrane group. However, since normal cells undergoing rapid mitosis are also sabotaged 
by cytotoxic agents, it is not surprising to observe hematological and gastrointestinal disorders 
(neutropenia, leukopenia, thrombocytopenia, diarrhea, nausea, and vomiting) [58] as side effects of 
Cabazitaxel. After balancing the benefits and risks, Cabazitaxel was approved by the FDA. However, 
it is not considered as a cost-effective therapy due to the incremental costs concerning adverse events 
and therefore it is not recommended by the National Institute for Health and Clinical Excellence [59]. 
5. Vaccine Sipuleucel-T 
Sipuleucel-T, launched in 2010, is mainly a set of antigen-presenting cells (APC) generated from 
the patient’s own hematopoietic progenitor cells. These APC are loaded with a fusing protein (PA2024) 
that consists of prostate acid phosphatase (PAP) conjugated with granulocyte-macrophage colony-stimulating 
factor (GM-CSF). After being infused back into the patients, Sipuleucel-T binds to the T cell receptors 
on the immature CD8+ cytotoxic T lymphocytes and subsequently endows these cells with PAP epitopes, 
which can further guide them to demolish PCa cells. As a vaccine, Sipuleucel-T also activates the 
helper CD4+ T lymphocytes, which not only attack the cancer cells directly, but also maintain other 
cytotoxic T lymphocytes via cytokine secretion. Depending on the initial leukapheresis, other cells, 
such as T cells, B cells and natural killer cells, can also be present in the final product [60]. Since PAP 
is employed as the navigating epitope, the expression of PAP in at least 25% of cancer cells is a 
premise. This personalized treatment invokes both humoral and T cell immune response. The IgM and 
IgG antibodies against PA2024 and PAP are augmented (titers exceeding 400) in 66.2% and 28.5% of 
the treated patients, both of which are around 20-fold higher compared to those ratios in the placebo 
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group [61]. Similarly, T-cell proliferation responses to PA2024 and PAP were observed to be much 
more frequent in Sipuleucel-T six weeks after the infusion [61]. After pooling the data obtained from 3 
phase III clinical trials [61–63], Sipuleucel-T demonstrates a 26.5% reduction in risk of death and 
accordingly an improvement of median overall survival of 4.1 months [60]. However, since the time to 
disease progression (radiographic or clinical events) as the primary end point do not show significant 
difference between Sipuleucel-T and placebo groups [61–63], the application of other medications, 
such as Docetaxel, might have an impact on the survival data. 
6. RANKL Antibody Denosumab 
Skeleton is the site most frequently showing PCa metastases. In CRPC patients, the incidence of 
bone metastases is nearly 90% [64]. These metastatic cancer cells promote bone resorption to release 
various growth factors that have been stored inside the bones in immobilized forms to stimulate their 
proliferation, such as platelet-derived growth factors, insulin-like growth factors, transforming growth 
factor and fibroblast growth factors [65]. Bone metastases cause severe symptoms, e.g., pain, 
pathologic fractures, spinal cord compression and hypercalcemia, which not only impair life quality, 
but also can be life-threatening. Moreover, long term application of androgen deprivation therapy (ADT) 
suppresses androgens and estrogens leading to the decline of bone mineral density (BMD) and an 
increased risk of fragility fractures. All these events are mediated via interrupting the balance of bone 
resorption and formation, in which the receptor activator of nuclear factor kappa B (RANK) and its 
ligand (RANKL) play important roles. RANKL expressed by both osteoblast and activated T cells 
stimulates the differentiation of osteoclast precursors after binding to the RANK on their membranes. 
Via activating the nuclear factor kappa B and Jun N-terminal kinase pathways, it further maintains the 
mature osteoclast cells, facilitates their adherence and ultimately augments bone resorption. It is 
notable that PCa cells in bone metastases but not in other sites also express RANKL [66]. Denosumab 
is a monoclonal antibody against RANKL approved in 2010 for bone related complications. In PCa 
patients under ADT with high fracture risks, it significantly increases the BMD at the lumbar spine (6.7%), 
total hip (4.8%) and whole body (4.0%) after 24 months [67]. This improvement is observed as early 
as one month after the application [67]. Accordingly, the total incidence of new vertebral fracture over 
a duration of three years (3.9%) is reduced by 62% compared to that in the placebo group [67]. 
Biomarkers of bone turnover, such as serum C-telopeptide, procollagen type I N-terminal peptide and 
TRAP-5b, are decreased as well [67]. Furthermore, Denosumab is superior to Zoledronic acid in 
preventing skeletal-related events (SRE) in CRPC patients with bone metastases (time to the first SRE 
of 20.7 vs. 17.1 months, respectively) [68]. It also causes stronger declines in the concentrations of 
urinary N-telopeptide and serum bone specific alkaline phosphatase, but no difference in PSA levels, 
investigator-reported disease progression and overall survival compared to Zoledronic acid [68]. These 
benefits are also observed in post-bisphosphonates patients [69]. More exciting is that Denosumab 
significantly improves the bone-metastasis-free survival to 29.5 months, which is 4.2 months longer 
than that of the placebo arm [70]. The time to the first bone metastasis is delayed to 33.2 months as 
well (vs. 29.5 months for placebo group) [70]. 
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7. Radiopharmaceutical Alpharadin 
Another drug targeting PCa bone metastases is Alpharadin (Xofigo, 233RaCl2), which was approved 
by the FDA on 15 May 2013. Alpharadin is a radiopharmaceutical and hence is more suitable for 
patients with multifocal bone diseases compared to external-beam radiation therapy. Although several 
radiopharmaceuticals have been employed in the clinic, such as Strontium-89, Samarium-153 and 
Rhenium-186, their major benefit is just pain palliation. In contrast, Alpharadin is the first and only 
radiopharmaceutical that demonstrates improvement on overall survival [71]. As a calcium mimic, 
Alpharadin can be maximally uptaken by the skeletal (40%–60% of the applied dose) after intravenous 
injection [72]. A ten-fold less amount is found in the red marrow compared to the bones and the 
distribution in other organs, such as brain, kidneys and adrenals, is very low [73]. Furthermore, Alpharadin 
mainly emits α-rays, which shows a track length shorter than 100 µm (about 2–10 cell diameters). All 
these special features added up, render alpharadin as causing less damage to normal tissues, especially 
bone marrow, than other radiopharmaceuticals and other radiation therapies. Alpharadin not only 
relieves pain in CRPC patients with bone metastasis, but also postpones the median time to first SRE 
by three weeks [71]. It reduces the median bone levels of alkaline phosphatase by 65.6%, which, in 
contrast, are increased by around 9% in the placebo arm [71]. Accordingly, PSA progression is 
delayed to 26 weeks in contrast to eight weeks in the control group [71]. The most significant 
achievement is the improvement of overall survival by 3.6 months [74], which has not been seen for 
other radiopharmaceuticals. 
8. Other Drug Candidates in Clinical Trials and Novel Strategies 
Besides these drugs approved recently, there are more drug candidates or new indications of 
launched drugs under evaluation in clinical trials (Table 1). Galeterone (Scheme 2) is a CYP17 
inhibitor but also shows AR antagonism activity. It down-regulates the expression of both wild type and 
mutated AR, blocks the AR nuclear translocation and the subsequent transcription [75]. A phase I clinical 
trial revealed PSA responses in around 20% of the patients and the according tumor regression [76].  
VT-464 (Scheme 2) is claimed to be a selective inhibitor of C17-20 lyase (one activity of CYP17) and 
is expected to avoid the secondary mineralocorticoid excess observed for Abiraterone. Experiments in 
rhesus monkeys confirm that it shows little influence on the concentrations of mineralocorticoids and 
glucocorticoids [77,78]. Its clinical trial results are expected to show whether this success can be 
translated into humans. Different from other cytotoxic agents, TH-302 (Scheme 2) is a prodrug specifically 
activated by hypoxia, which is a common feature inside tumors, but not normal tissues. Fewer side 
effects are therefore expected than observed after other chemotherapies [79]. PROSTVAC-VF, as a 
pox viral vaccine expresses PSA and three T-cell co-stimulatory molecules, i.e., B7.1, intercellular 
adhesion molecule-1 and leukocyte function-associated antigen-3. Due to the employment of viral 
vectors (vaccinia and fowlpox viruses), potent immune responses are induced and APCs are thus 
endowed with PSA epitopes. These APCs subsequently activate CD8+ cytotoxic T lymphocytes and 
helper CD4+ T lymphocytes, which further attack PCa cells. The application of PROSTVAC-VF not 
only inhibits the proliferation of cancer cells, but also significantly reduces the tumor growth rate [80]. 
The latter may explain a phenomenon often observed with vaccines that improved overall survival is 
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not accompanied by a delayed time to progression. Besides cancer vaccines, the blockade of immune 
checkpoints, e.g., cytotoxic T-lymphocyteassociated antigen-4 (CTLA-4) and programmed death 1 (PD-1), 
is another promising strategy being extensively investigated. These immune checkpoints are expressed 
on activated T-cells and serve as modulators to reduce and terminate immuno responses. This 
physiological function, however, can potentially be exploited by tumor cells to develop resistance [81]. 
Currently, anti-CTLA-4 antibody Ipilimumab [82] and anti-PD-1 antibody Nivolumab [83] are under 
evaluation in clinical trials and promising results are reported. Moreover, a heat shock protein 27 
inhibitor (OGX-427), various kinase inhibitors, platinum complexes and other entities with different 
mechanisms are currently also being evaluated as treatments for CRPC (Table 1). 
Table 1. Drug candidates for the treatment of castration-resistant prostate cancer (CRPC). 
Entity a Category b Mechanism c Clinical Trials d  
Orteronel [84] 
(TAK700) 
SM CYP17 inhibitor 





Phase III  
(NCT01707966, NCT01193257[P], 
NCT01809691[G]; NCT01546987[BG]) 
Galeterone [75,76]  
(TOK-001) 
SM 
CYP17 inhibitor with 
AR antagonism 
phase I/II  
(NCT00959959#, NCT01709734) 
VT-464 [77,78] SM 
selective CYP17  
C17-20 lyase inhibitor 
phase I/II  
(2011-004103-20) e 
CFG920 SM CYP17 inhibitor 
phase I/II  
(NCT01647789) 
ARN-509 [85] SM AR antagonist 
phase I/II  
(NCT01822041, NCT01171898, 
NCT01792687[AP], NCT01790126/[G]) 
ODM-201 [86] SM AR antagonist 
phase I/II  
(NCT01429064, NCT01784757, NCT01317641) 
AZD-3514 SM AR mRNA antagonist 
Phase I  
(NCT01337518) 
EZN-4176 [87] AO 
down-regulation of 
AR mRNA 
Phase I  
(NCT01337518) 
OGX-427 [88] AO 
heat shock protein 27 
inhibitor 
Phase I/II  









Phase I/II  





Phase III  
(NCT01605227, NCT01522443) 
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Table 1. Cont. 
Entity a Category b Mechanism c Clinical Trials d  
Dasatinib [90] SM 
Src tyrosine kinase 
inhibitor 
Phase I/II  
(NCT00570700, NCT00918385,  
NCT01260688[C], NCT01685125[AP],  
NCT00385580, NCT00385580#,  







Phase I/II  






inhibitor of VEGFR, 
PDGFR and Raf 
kinase 
Phase I/II  
(NCT00466752#, NCT00090545#,  
NCT00405210[D]#, NCT00619996[D]#,  
NCT00424385[I]#, NCT00093457#,  





SM BCR-Abl inhibitor 
Phase I/II  
(NCT00080678[D]#, NCT00251225[D]#,  






inhibitor of VEGFR / 
PDGFR 
Phase I/II  
(NCT00879619[DP], NCT00299741#,  
NCT00137436[DP]#, NCT00790595#,  
NCT00672594, NCT00631527[GR]#,  
NCT00879619[DP], NCT00748358,  






VEGF trap,  
anti-angiogensis 
Phase III  
(NCT00519285[D]#) 
TH-302 [79] SM 
hypoxia activated 
cytotoxicity 
Phase I/II  
(NCT00743379) 
Carboplatin [95]  PtC 
cytotoxicity; inhibiting 
DNA synthesis 
Phase I/II  
(NCT01051570[EP], NCT00973882[Ep]#,  
NCT00049257[Pt]#, NCT01505868[Ct],  
NCT00017576[Ca]#, NCT00514540[D]#,  
NCT00134706[D]#, CT00005627 [DEs]#,  
NCT00183924[DEs]#, NCT00016913,  
NCT00193193[EsPt]#, NCT01558492[Pt],  
NCT00003690[Fp]#, NCT00675545[D]#, 
NCT00005810[DEsFg]#) 
Oxaliplatin [96] PtC 
cytotoxicity; inhibiting 
DNA synthesis 
Phase I/II  
(NCT01338792[Pe]#, NCT00260611[D]#, 
NCT01487720[Gm]) 
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Table 1. Cont. 
Entity a Category b Mechanism c Clinical Trials d  
Satraplatin [97] PtC 
cytotoxicity; inhibiting 
DNA synthesis 
Phase II  
(NCT00499694[Bv], NCT00634647[P])  
Phase III  
(NCT00069745[P]#) 
Bevacizumab [98] AB angiogenesis inhibitor 
Phase II  
(NCT00349557[GR]#, NCT00478413,  
NCT00776594[BG], NCT00658697[BDG],  
NCT00027599[S]#, NCT00942578[DLP]#,  
NCT00499694[Sp], NCT00089609[DPT],  
NCT00574769[DEl], NCT00321646[D]#, 
NCT00348998[BGR])  







virus expresses PSA 
Phase I/II  
(NCT00450463[F], NCT00078585,  
NCT00108732, NCT00113984,  
NCT00096551#, NCT00001382#,  
NCT00045227#, NCT00020254#,  
NCT00003871#, NCT00004029#)  
Phase III  
(NCT01322490) 
Ipilimumab [82] 







receptor 4 antibody 
Phase I/II  
(NCT01530984, NCT01377389[G],  
NCT01194271[G], NCT01688492,  
NCT01498978, NCT00323882,  
NCT01832870[S], NCT00064129,  
NCT01804465, NCT00170157#,  
NCT00050596/[D]#, NCT00113984#)  







anti programmed cell 
death protein 1 
antibody 
Phase I/II  
(NCT00441337#) 
Custirsen [99]  
(OGX-011) 
AO clusterin inhibitor 
Phase I/II  
(NCT00327340[D]#, NCT00054106[GF]#,  
NCT00258388[DP]#, NCT00471432[D]#)  








Phase I/II  
(NCT00090363#, NCT00055471#,  
NCT00314782[D]#, NCT01168141)  
Phase III  
(NCT00554229#, NCT00626548, 
NCT00617669[D]#) 
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Table 1. Cont. 
Entity a Category b Mechanism c Clinical Trials d  
Atrasentan [101] SM 
endothelin-A receptor 
antagonist 
Phase I/II  
(NCT00181558[Z]#, NCT00038662#)  






Phase I/II  
(NCT01513733[CtP], NCT01732549, 
NCT00560482)  
Phase III  
(NCT01234311) 
a For the structures of small molecules, see Scheme 2. For more information, see references noted;  
b SM: small molecule; AO: antisense oligonucleotide; P: protein; AB: antibody; V: vaccine; PtC: platinum complex; 
PA: peptide analogue; c VEGFR: vascular endothelial growth factor receptor; PDGFR: platelet-derived 
growth factor receptor; d in combination with [A]: Abiraterone; [B]: Bicalutamide; [Bv]: Bevacizumab;  
[C]: Cediranib; [Ca]: Calcitriol; [Cp]: Cisplatin; [Ct]: Cabazitaxel; [D]: Docetaxel; [Da]: Dasatinib;  
[E]: Everolimus; [El]: Everolimus; [Ep]: Etoposide; [Es]: Estramustine; [F]: Flutamide; [Fg]: Filgrastim; 
[Fp]: Flavopiridol; [G]: GnRH analogue; [Gm]: Gemcitabine; [I]: Imatinib; [L]: Lenalidomide; [Op]: Oxaliplatin; 
[P]: Prednisone; [Pe]: Pemetrexed; [Pt]: Paclitaxel; [R]: radiation; [S]: Sipuleucel-T; [So]: Sorafenib;  
[Sp]: Satraplatin; [T]: Thalidomide; [Z]: Zoledronic acid; /: monotherapy or in combination; #: accomplished; 
e registered in the EudraCT database (www.clinicaltrialsregister.eu). 
Scheme 2. Structures of small molecule drug candidates in clinical trials for CRPC. 
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Scheme 2. Cont. 
Furthermore, some AR mutations induced by the long term application of ADT have been identified 
that can be activated by glucocorticoids, in particular cortisol, and thus lead to resistance [103]. Dual 
inhibition of CYP17/CYP11B1, which is responsible for the biosynthesis of cortisol, is therefore 
proposed as a novel strategy for the PCa patients with such mutated AR [104]. ADT is also associated 
with increased cardiovascular mortality [105], while the incidence of cardiac disorders is elevated 
under Abiraterone treatment as well [41,42]. This is mediated by exorbitant aldosterone, which is a 
consequence of androgen deficiency caused via various mechanisms, such as the increase of serum 
low- and high-density lipoprotein (reviewed in reference 106). Since CYP11B2 is the crucial enzyme 
in the production of aldosterone, dual inhibition of CYP17/CYP11B2 is proposed to reduce the risks of 
cardiovascular diseases in PCa patients [106]. 
9. Conclusions 
Six drugs have been launched for the treatment of castration-resistant prostate cancer since 2010, 
i.e., CYP17 inhibitor Abiraterone, AR antagonist Enzalutamide, cytotoxic agent Cabazitaxel, 
vaccine Sipuleucel-T, RANKL antibody Denosumab and radiopharmaceutical Alpharadin. These 
drugs demonstrate improvement on the overall survival or symptoms relief and prolongation of 
bone-metastasis-free survival. More drug candidates with various mechanisms or new indications of 
launched drugs are currently under evaluation in clinical trials. Novel strategies are also proposed to 
further potentiate the antitumor effects or reduce treatment related side effects and complications. This 
progress gives CRPC patients hope for a longer life and better life quality. However, resistance to 
Abiraterone [107] and Enzalutamide [108] has been observed within 12–36 months after initiating the 
therapies. This resistance to hormone therapy is probably mediated by ligand-independent AR 
activation and up-regulation of AR and steroidogenic enzymes. Therefore, more investigations should 
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be performed on the optimal combination or the sequence of treatments needed to delay or reverse the 
resistance and thus maximize the clinical benefits for the patients. 
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